Psychological Morbidity in patients with Idiopathic Hirsutism presenting for Laser Treatment at a Tertiary Care Hospital

  • Aqsa Naheed
  • Aalia Akhtar Hayat
  • Qurat ul Ain
  • Bushra Razzaque
  • Sundus Fatima HITEC Institute of Medical Sciences
  • Nasser Dar
Keywords: hirsutism, psychiatric morbidity, PCOS, DASS 21, depression, anxiety, stress,Ferriman and Gallwey


Objective: The objective of our study was to determine the frequency of depression, anxiety, and stress in females presenting for laser treatment of hirsutism at a dermatology clinic.

Materials and Methods: This was a cross-sectional descriptive study. 152 female participants of all ages presenting for laser treatment of hirsutism to the dermatology department –removed for blind review--from June 2019 to Dec 2019, were included using a consecutive convenient sampling technique. Patients having an FG (Ferriman and Gallwey) score of 8 or more, were included whereas those having any underlying cause (as assessed by history and examination and laboratory investigations where required) for both hirsutism and psychological disorder were excluded. The participants were given an Urdu version of the DASS 21 (depression, anxiety, and stress scale) to complete.

Results: The participants had a mean age of 30.22 (SD = 9.17). The prevalence of depression, anxiety, and stress in the sample was found to be 13.2%, 23.7%, and 17.8%, respectively. Mean depression, anxiety, and stress scores on DASS 21 were 4.43(SD=4.87, Cut-off= 10), 4.34(SD=5.12, Cut-off= 8), and 8.21(SD=6.26, Cut-off=15), respectively, indicating that the scores were within the normal range. Anxiety was the most common illness in the sample and both depression and stress showed a decline with advancing age up till 45years of age. No statistically significant association was found between the severity of hirsutism and depression, stress, and anxiety scores.

Conclusion: Psychological morbidity was found to be lower in patients of idiopathic hirsutism presenting for laser treatment. The long-term efficacy of laser treatment needs further evaluation in future research.


1. Matheson E, Bain J. Hirsutism in Women. Am Fam Physician. 2019 01;100(3):168–75.
2. Pasch L, He SY, Huddleston H, Cedars MI, Beshay A, Zane LT, et al. Clinician vs. Self-ratings of Hirsutism in Patients With Polycystic Ovarian Syndrome: Associations With Quality of Life and Depression. JAMA Dermatol. 2016 01;152(7):783–8.
3. Anjum MU, Yasmin S, Riaz H, Shah SH. HIRSUTISM. The Professional Medical Journal. 2016 Jun 10;23(06):741–5.
4. Chaudhari AP, Mazumdar K, Mehta PD. Anxiety, Depression, and Quality of Life in Women with Polycystic Ovarian Syndrome. Indian J Psychol Med. 2018 Jun;40(3):239–46.
5. Kumari R, Shaikh IA, Abbasi R, Tarbani K, Kumari M. Efficacy and safety of intense pulse light in idiopathic hirsutism. J Pak Assoc Dermatol. 2019 Sep 1;29(1):78–82.
6. Pate C. Issues Faced by Women With Hirsutism: State of the Science. Health Care Women Int. 2016 Jun;37(6):636–45.
7. Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. American family physician. 2016 Jul 15;94(2):106-13
8. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961;21(11):1440–7.
9. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): construct validity and normative data in a large non-clinical sample. Br J Clin Psychol. 2005 Jun;44(Pt 2):227–39.
10. Aslam N, Kamal A. Translation, validation and effectiveness of depression, anxiety and stress (Dass-21) in assessing the psychological distress among flood affected individuals. J Pak Psychiatr Soc. 2017;14(4):16–20.
11. Borghi L, Leone D, Vegni E, Galiano V, Lepadatu C, Sulpizio P, et al. Psychological distress, anger and quality of life in polycystic ovary syndrome: associations with biochemical, phenotypical and socio-demographic factors. J Psychosom Obstet Gynecol. 2018 Apr 3;39(2):128–37.
12. Bano S, Mohammad N, Yousafzai AW. Socio-economic factors for depression in women of northern pakistan: a case-control study. KHYBER Med Univ J. 2020 Sep 30;12(3):183–7.
13. Gadit AAM, Mugford G. Prevalence of depression among households in three capital cities of Pakistan: need to revise the mental health policy. Plos One. 2007;2(2):e209.
14. Mirza I, Jenkins R. Risk factors, prevalence, and treatment of anxiety and depressive disorders in Pakistan: systematic review. Bmj. 2004;328(7443):794.
15. Rahman A, Ahmed M, Sikander S, Malik A, Tomenson B, Creed F. Young, single and not depressed: prevalence of depressive disorder among young women in rural Pakistan. J Affect Disord. 2009 Sep;117(1–2):42–7.
16. Tan J, Wang Q-Y, Feng G-M, Li X-Y, Huang W. Increased Risk of Psychiatric Disorders in Women with Polycystic Ovary Syndrome in Southwest China. Chin Med J (Engl). 2017 Feb 5;130(3):262–6.
17. Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017 May 1;32(5):1075–91.
How to Cite
Naheed A, Hayat A, Ain Q, Razzaque B, Fatima S, Dar N. Psychological Morbidity in patients with Idiopathic Hirsutism presenting for Laser Treatment at a Tertiary Care Hospital. JRMC [Internet]. 30Sep.2021 [cited 4Dec.2021];25(3):345-50. Available from: